Phreesia (PHR) Form 144 Shows 3,133 Shares from Vesting to Be Sold
Rhea-AI Filing Summary
Form 144 filing for Phreesia, Inc. (PHR) shows a proposed sale of 3,133 common shares with an aggregate market value of $72,950.03. The shares were acquired on 09/11/2025 through restricted stock vesting and payment classified as compensation. The planned sale date is 09/16/2025 on the NYSE. The filer reported a prior sale within three months: 1,245 shares sold on 07/17/2025 for $33,472.82. The filing lists total outstanding shares as 59,914,473. Several standard identifying fields (issuer address, filer CIK/CCC, and named filer contact) are not provided in the visible content.
Positive
- Transaction disclosure includes acquisition date, nature (restricted stock vesting), sale date, broker, and aggregate value
- Three‑month sales history provided (1,245 shares sold on 07/17/2025 for $33,472.82), meeting disclosure requirements
Negative
- Key identifying fields missing in the provided excerpt (filer CIK/CCC and issuer name/address/contact information are not shown)
- Limited context: filing contains only securities sale details and attestation; no operational or financial information about the issuer is included
Insights
TL;DR: Routine insider sale tied to recently vested restricted stock; size is negligible relative to outstanding shares.
The filing documents a proposed sale of 3,133 common shares acquired by restricted stock vesting and classified as compensation. At an aggregate value of $72,950.03, this represents roughly 0.0052% of the reported 59,914,473 shares outstanding, indicating the transaction is immaterial to capitalization metrics. A prior sale of 1,245 shares on 07/17/2025 for $33,472.82 is disclosed, satisfying the three‑month sales history requirement. There are no earnings or operational details in this filing to reassess company fundamentals.
TL;DR: Filing appears to satisfy Rule 144 disclosure elements but lacks some issuer/filer identifiers in the provided excerpt.
The notice includes required transaction details: class, number of shares, acquisition date, nature of acquisition (restricted stock vesting), sale date, broker, and recent three‑month sales. However, the provided content omits specific filer identification fields (CIK/CCC) and issuer contact/address information, which are typically present on a complete Form 144. The signer declares no undisclosed material adverse information, consistent with the form's attestation language.